LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

Strona główna・Stock List・Arrowhead Pharmaceuticals Inc

Arrowhead Pharmaceuticals Inc

Closed

SectorHealthcare

41.23 0.17

Buy Sell

Overview

Share price change

24h

Current

Min

40.79

Max

41.77

Key metrics
By Trading Economics
Income	-547M -179M
Sales	-515M 28M
Profit margin	-643.397
Employees	609
EBITDA	-546M -148M

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	+8.68% upside

Dividends
By Dow Jones
Next Earnings	25 lis 2025

Market Stats
By TradingEconomics
Market Cap	3.1B 5.4B
Previous open	41.06
Previous close	41.23

News Sentiment

By Acuity

16%

84%

15 / 374 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Weak Bearish Evidence

11.5 / 12.23 Support & Resistance

Arrowhead Pharmaceuticals Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

14 lis 2025, 17:45 UTC

Earnings

Major Market Movers

Figure Technology Shares Rise After Higher 3Q Earnings, Revenue

14 lis 2025, 17:31 UTC

Earnings

Major Market Movers

American Bitcoin Advances on 3Q Profit, Eric Trump's Crypto Confidence

14 lis 2025, 16:15 UTC

Major Market Movers

Scholar Rock Shares Rise on Renewed Apitegromab Hopes

14 lis 2025, 23:56 UTC

Acquisitions, Mergers, Takeovers

Berkshire Hathaway Bought Alphabet Shares Worth $4.3 Billion in the Third Quarter. Here's What It Sold. -- Barrons.com

14 lis 2025, 23:02 UTC

Market Talk

Chinese Battery Makers Benefit From U.S. Rising Demand -- Market Talk

14 lis 2025, 22:35 UTC

Earnings

Acquisitions, Mergers, Takeovers

The Score: Tyson, Robinhood, Walmart, Paramount Skydance and More Stocks That Defined the Week -- WSJ

14 lis 2025, 22:32 UTC

Acquisitions, Mergers, Takeovers

Berkshire Buys Shares of Alphabet and Further Pares Apple Stake -- 2nd Update

14 lis 2025, 22:29 UTC

Earnings

Starbucks Scores on Holiday Sales. It's a Good Sign for the Turnaround. -- Barrons.com

14 lis 2025, 22:00 UTC

Acquisitions, Mergers, Takeovers

Berkshire Buys Shares of Alphabet and Further Pares Apple Stake -- Update

14 lis 2025, 21:50 UTC

Market Talk

Earnings

Tech, Media & Telecom Roundup: Market Talk

14 lis 2025, 21:18 UTC

Acquisitions, Mergers, Takeovers

Berkshire Buys Shares of Alphabet and Pares Apple Stake -- WSJ

14 lis 2025, 20:27 UTC

Market Talk

Oil Futures Rise After Ukraine Strikes Russian Port -- Market Talk

14 lis 2025, 20:23 UTC

Market Talk

U.S. Natural Gas Futures Post Weekly Gain -- Market Talk

14 lis 2025, 20:17 UTC

Acquisitions, Mergers, Takeovers

Several State Attorneys General Oppose Railroad Merger -- WSJ

14 lis 2025, 19:29 UTC

Market Talk

Earnings

Applied Materials' F4Q Results Seen as 'Uninspiring' -- Market Talk

14 lis 2025, 18:44 UTC

Market Talk

Earnings

Disney's Growth Now Hinges More on ESPN -- Market Talk

14 lis 2025, 18:27 UTC

Market Talk

Global Equities Roundup: Market Talk

14 lis 2025, 18:27 UTC

Market Talk

Morgan Stanley Sees 'Worthy Successor' in Walmart CEO Furner -- Market Talk

14 lis 2025, 18:20 UTC

Market Talk

U.S. Oil Rig Count Rises by 3 to 417 -- Market Talk

14 lis 2025, 17:20 UTC

Market Talk

Earnings

Auto & Transport Roundup: Market Talk

14 lis 2025, 17:20 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Health Care Roundup: Market Talk

14 lis 2025, 17:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

14 lis 2025, 16:51 UTC

Market Talk

Starbucks Gets Holiday Sales Lift -- Market Talk

14 lis 2025, 16:48 UTC

Market Talk

Gold Slides Amid Selloff, Lower December Fed Rate-Cut Expectations -- Market Talk

14 lis 2025, 16:38 UTC

Market Talk

Unica Reports Higher Brazilian Sugar and Ethanol Production -- Market Talk

14 lis 2025, 16:30 UTC

Acquisitions, Mergers, Takeovers

Merck Is Paying Up for Flu Biotech as M&A Spree Continues -- Barrons.com

14 lis 2025, 16:28 UTC

Market Talk

Ukraine Strike on Russian Port Lifts Distillates -- Market Talk

14 lis 2025, 15:59 UTC

Market Talk

U.S. Natural Gas Inventories Rise More Than Expected -- Market Talk

14 lis 2025, 15:06 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

14 lis 2025, 15:06 UTC

Market Talk

Dollar Could Benefit From U.K., French Fiscal Concerns -- Market Talk

Peer Comparison

Price change

Arrowhead Pharmaceuticals Inc Forecast

Price Target

By TipRanks

8.68% upside

12 Months Forecast

Average 44.71 USD 8.68%

High 80 USD

Low 17 USD

Based on 9 Wall Street analysts offering 12 month price targets forArrowhead Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

9 ratings

Buy

Hold

Sell

Based on 9 analysts giving stock ratings to Arrowhead Pharmaceuticals Inc - Dist in the past 3 months.

Technical Score

By Trading Central

11.5 / 12.23Support & Resistance

Recent bearish events outweigh bullish events.

Bearish events outweigh bullish events.

There is one bearish event.

Sentiment

By Acuity

15 / 374 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Arrowhead Pharmaceuticals Inc

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.